Cyllene Therapeutics secured a $37 million Series C round to push EG110A through late-stage clinical development in severe neurogenic bladder conditions. The company’s funding plan targets progression of its lead gene therapy program, reflecting continued capital support for gene-delivery approaches in urology. For investors and pipeline watchers, the round highlights that gene therapy is moving beyond rare monogenic diseases into broader indications where delivery and durability are key differentiators. The financing also signals confidence in EG110A’s clinical momentum as it approaches later-stage milestones. With larger late-stage studies often requiring substantial manufacturing and clinical expansion, the Series C provides runway for scaling execution while advancing safety and efficacy data collection.